Abstract:OBJECTIVE: Pulmonary hypertension (PH) is a progressive disease with vascular remodeling as a critical structural alteration. We have previously shown that metabolic reprogramming is an early initiating mechanism in animal models of PH. This metabolic dysregulation has been linked to remodeling the mitochondrial network to favor fission. However, whether the mitochondrial fission/fusion balance underlies the metabolic reprogramming found early in PH development is unknown.METHODS: Utilizing a rat early model of PH, in conjunction with cultured pulmonary endothelial cells (PECs), we utilized metabolic flux assays, Seahorse Bioassays, measurements of electron transport chain (ETC) complex activity, fluorescent microscopy, and molecular approaches to investigate the link between the disruption of mitochondrial dynamics and the early metabolic changes that occur in PH.RESULTS: We observed increased fusion mediators, including Mfn1, Mfn2, and Opa1, and unchanged fission mediators, including Drp1 and Fis1, in a two-week monocrotaline-induced PH animal model (early-stage PH). We were able to establish a connection between increases in fusion mediator Mfn1 and metabolic reprogramming. Using an adenoviral expression system to enhance Mfn1 levels in pulmonary endothelial cells and utilizing 13C-glucose labeled substrate, we found increased production of 13C lactate and decreased TCA cycle metabolites, revealing a Warburg phenotype. The use of a 13C5-glutamine substrate showed evidence that hyperfusion also induces oxidative carboxylation. The increase in glycolysis was linked to increased hypoxia-inducible factor 1α (HIF-1α) protein levels secondary to the disruption of cellular bioenergetics and higher levels of mitochondrial reactive oxygen species (mt-ROS). The elevation in mt-ROS correlated with attenuated ETC complexes I and III activities. Utilizing a mitochondrial-targeted antioxidant to suppress mt-ROS, limited HIF-1α protein levels, which reduced cellular glycolysis and reestablished mitochondrial membrane potential.CONCLUSIONS: Our data connects mitochondrial fusion-mediated mt-ROS to the Warburg phenotype in early-stage PH development.

Metabolic reprogramming, oxidative stress, and pulmonary hypertension

Mitochondrial Metabolism, Redox, and Calcium Homeostasis in Pulmonary Arterial Hypertension

Mitochondrial dysfunction in pulmonary arterial hypertension

Metabolism, Mitochondrial Dysfunction, and Redox Homeostasis in Pulmonary Hypertension

Mitochondrial network dynamics in pulmonary disease: Bridging the gap between inflammation, oxidative stress, and bioenergetics

Mitochondrial dysfunction and pulmonary hypertension: cause, effect, or both.

Acquired disorders of mitochondrial metabolism and dynamics in pulmonary arterial hypertension

Metabolic reprogramming: A novel metabolic model for pulmonary hypertension

Mitochondrial hyperfusion induces metabolic remodeling in lung endothelial cells by modifying the activities of electron transport chain complexes I and III

Emerging insights into pulmonary hypertension: the potential role of mitochondrial dysfunction and redox homeostasis

[Metabolic reprogramming in pulmonary hypertension].

Important Functions and Molecular Mechanisms of Mitochondrial Redox Signaling in Pulmonary Hypertension

New Insights into the Implication of Mitochondrial Dysfunction in Tissue, Peripheral Blood Mononuclear Cells, and Platelets during Lung Diseases

Mechanisms of lung endothelial cell injury and survival in pulmonary arterial hypertension

Endothelial Cell Energy Metabolism, Proliferation, and Apoptosis in Pulmonary Hypertension

Metabolic Deregulation in Pulmonary Hypertension

Mitochondria as a primary determinant of angiogenic modality in pulmonary arterial hypertension

Unveiling the metabolic landscape of pulmonary hypertension: insights from metabolomics

Mitochondrial Dysfunction as a Pathogenic Mediator of Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis

Glycolysis modulation: New therapeutic strategies to improve pulmonary hypertension (Review)

Functions and novel regulatory mechanisms of key glycolytic enzymes in pulmonary arterial hypertension